Veeva Systems Inc. (VEEV) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $162.49, but acceptable to hold if already in. Reasons: Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.4): -0.5.
Veeva provides cloud software, data, and business consulting exclusively for the global life sciences industry across R&D, quality, and commercial functions for 1,552 customers as of January 2026. Revenue is primarily subscription-based; top 10 customers accounted for 28% of... Read more
Hold if already holding. Not a fresh buy at $162.49, but acceptable to hold if already in. Reasons: Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.4): -0.5. Chart setup: RSI 54 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-11Recent Developments — Veeva Systems Inc.
Latest news
- NEWS Bogart Wealth LLC Grows Stake in Veeva Systems Inc. $VEEV - MarketBeat — MarketBeat positive
- NEWS /C O R R E C T I O N -- Veeva Systems/ - PR Newswire — PR Newswire neutral
- NEWS Merck KGaA, Darmstadt, Germany Selects Veeva Vault CRM Worldwide - PR Newswire — PR Newswire positive
- NEWS Veeva Systems (VEEV) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Reasons to Add Veeva Systems Stock to Your Portfolio for Now - The Globe and Mail — The Globe and Mail positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop 10 customers28%10-K Item 1A: 'our top 10 customers accounted for 28% of our total revenues'
- MEDIUMGeographiccustomers outside North America40%10-K Item 1A: 'customers outside North America accounted for approximately 40% of our total revenues'
- HIGHCustomerlife sciences industry10-K Item 1A: 'Nearly all of our revenues are generated by sales to customers in the life sciences industry'
Material Events(8-K, last 90d)
- 2026-04-20Item 5.02LOWJosh Faddis, SVP General Counsel, announced retirement effective November 1, 2026; will transition to part-time advisor. Veeva will appoint a successor upon his transition. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $162.49, but acceptable to hold if already in. Reasons: Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.4): -0.5. Chart setup: RSI 54 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $223.46 (+37.5%), stop $151.34 (−7.4%), A.R:R 3.5:1. Score 5.7/10, moderate confidence.
Take-profit target: $223.46 (+37.3% upside). Target $223.46 (+37.5%), stop $151.34 (−7.4%), A.R:R 3.5:1. Stop-loss: $151.34.
Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.4): -0.5; Negative momentum.
Veeva Systems Inc. trades at a P/E of 29.1 (forward 16.3). TrendMatrix value score: 6.4/10. Verdict: Hold.
36 analysts cover VEEV with a consensus score of 3.9/5. Average price target: $248.
What does Veeva Systems Inc. do?Veeva provides cloud software, data, and business consulting exclusively for the global life sciences industry across...
Veeva provides cloud software, data, and business consulting exclusively for the global life sciences industry across R&D, quality, and commercial functions for 1,552 customers as of January 2026. Revenue is primarily subscription-based; top 10 customers accounted for 28% of total revenues across fiscal years ended January 2026, 2025, and 2024. Non-North America customers were approximately 40% of fiscal 2026 revenues.